A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD

Abstract

Fluticasone furoate/vilanterol trifenatate (FF/VI) is a once-daily inhaled corticosteroid/longacting b 2 -agonist combination in development for chronic obstructive pulmonary disease (COPD) treatment. We compared the efficacy and safety of FF/VI versus fluticasone propionate/salmeterol (FP/SAL) twice daily over 12 weeks.Moderate to very severe COPD patients received FF/VI 100/25 mg once daily in the morning (n5266) or FP/SAL 500/50 mg twice daily (n5262). The primary end-point was a change from baseline in 0-24 h weighted mean forced expiratory volume in 1 s (wmFEV1) at 12 weeks. Additional end-points included time to 100 mL improvement from baseline on day 1 and a change from baseline in St George's Respiratory Questionnaire (SGRQ). Safety was also assessed.wmFEV1 (mean 130 mL) was greater and time to 100 mL improvement shorter (median 16 min) with FF/VI than FP/SAL (weighted mean 108 mL, median 28 min). Health status (SGRQ total score) improved in both groups (FF/VI -4.3 units, FP/SAL -3.0 units). Differences between treatments were not statistically significant. Six patients in the FF/VI (2%) and three in the FP/SAL (1%) arm experienced serious adverse events, none of which were considered to be drug related.Improvements in lung function and health status were not significantly different between FF/VI 100/ 25 mg once daily and FP/SAL 500/50 mg twice daily; there was no apparent difference between the safety profiles of either therapy. @ERSpublications Once-daily fluticasone furoate/vilanterol trifenatate and twice-daily fluticasone propionate/ salmeterol act similarly

Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment

“…Many new treatments for COPD have been recently released or are about to be launched [11][12][13][14]. They include mostly new LABD, ICS and various combinations of these agents.…”

Long-acting bronchodilators in COPD: where are we now and where are we going?

“…However, it should be noted that benefits over a twice-daily ICS/LABA comparator were not shown [67]. In view of the fact that mometasone is effective when it is administered once daily, a fixed dose combination of mometasone and indacaterol (QMF149) administered via the Breezhaler device (Novartis) is being evaluated in patients with COPD, but no clinical data have yet been published [41].…”

Frischer Wind für COPD-geplagte Lungen

“…Die neueste Entwicklung ist die Fluticasonfuorat (92 µg)/Vilanterol (22 µg)-Fixkombination im Ellipta®-Inhaler [17,22]. Das Besondere daran ist die tägliche Einmalgabe [23][24][25][26]. Sie war in Bezug auf die FEV 1 -Verbesserung der Zweimalgabe der alten Fluticason/Salmeterol-Fixkombination nicht überle-gen [24].…”